TORONTO, Nov. 30 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today announced the placement of its proprietary sepsis diagnostics system, the Endotoxin Activity Assay (EAA(TM)) at the Klinikum Grosshadern, of the Ludwig-Maximillians University of Munich. The clinical usage of the assay will be directed by Dr. Eugen Faist, Professor of Surgery. Professor Faist is a recognized world leader in the areas of Sepsis and Trauma. He will be the Congress Chairman for the 7th World Congress on Trauma, Shock, Inflammation and Sepsis to be held in Munich, Germany in March 2007, where further studies on the clinical utility of the EAA(TM) will be presented by speakers from around the world. "This placement is another significant step in the commercialization of Spectral's EAA(TM) assay" stated Dr. Paul Walker, President and CEO of Spectral. "We are very pleased to be working with Dr. Faist because of his extensive experience and solid reputation in the area of sepsis and critical care". "We are pleased to have the EAA(TM) installed in our hospital. In combination with other biomarkers, the EAA(TM) offers a new light on the horizon to identify patients and facilitate timely clinical diagnosis", added Dr. Faist. Spectral continues to establish the EAA(TM) assay in leading hospitals with world renowned clinicians. Two more significant sites in Paris, France and Brussels, Belgium are scheduled for installation this quarter. These placements are key with respect to the ongoing support of our commercial distributors and their marketing efforts in Europe. Spectral is a developer of innovative technologies for rapid diagnostics in areas where accurate and timely information can make a significant impact on patient outcomes. Information from Spectral products contributes to early initiation of appropriate and targeted therapy. Current products include rapid diagnostics for sepsis (EAA(TM)) and West Nile Virus as well as a range of other biological reagents. Spectral's common shares are listed on The Toronto Stock Exchange: SDI. Information in this news release that is not current or historically factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, the future outlook of Spectral and anticipated events or results are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. %SEDAR: 00002006E